ReviewJournal of microbiology (Seoul, Korea)2021
Raloxifene as a treatment option for viral infections.
Review in Journal of microbiology (Seoul, Korea), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 43 citations in OpenAlex.
- Bone health and chronic viral infections: A narrative literature review.World journal of virology · 2026Review
- Nanotechnology-Driven Therapeutic Potential of Raloxifene in Osteoporosis and Cancer: A Recent Review.Current pharmaceutical design · 2026Review
- SARS-CoV-2 Entry Can Be Mimicked inViruses · 2025Article
- A Multi-Model Machine Learning Framework for Identifying Raloxifene as a Novel RNA Polymerase Inhibitor from FDA-Approved Drugs.Current issues in molecular biology · 2025Article
- Bibliometric Analysis of The Global Research Trends on The Application of Tamoxifen in The Treatment of Breast Cancer Over The Past 50 Years.The Malaysian journal of medical sciences : MJMS · 2025Review
- An Integrated Machine Learning Framework for Developing and Validating a Diagnostic Model of Hub Genes Related to Lipid Metabolism in Chronic Rhinosinusitis.Journal of inflammation research · 2025Article
- Retrospective Analysis of the Effect of Postmenopausal Women Medications on SARS-CoV-2 Infection Progression.Life (Basel, Switzerland) · 2024Article
- RNA splicing factor RBFOX2 is a key factor in the progression of cancer and cardiomyopathy.Clinical and translational medicine · 2024Review
- Enhanced oral bioavailability of levormeloxifene and raloxifene by nanoemulsion: simultaneous bioanalysis using liquid chromatography-tandem mass spectrometry.Nanomedicine (London, England) · 2024Article
- The potential renoprotective effect of Raloxifene in renal ischemia-reperfusion injury in a male rat model.Journal of medicine and life · 2023Article
- Multimodal representation learning for predicting molecule-disease relations.Bioinformatics (Oxford, England) · 2023Article
- Rapid discovery and classification of inhibitors of coronavirus infection by pseudovirus screen and amplified luminescence proximity homogeneous assay.Antiviral research · 2023Article
- The SARS-CoV-2 spike protein binds and modulates estrogen receptors.Science advances · 2022Article
- Inhibition of KIF20A suppresses the replication of influenza A virus by inhibiting viral entry.Journal of microbiology (Seoul, Korea) · 2022Article
- A phase 2 randomized, double-blinded, placebo-controlled, multicenter trial evaluating the efficacy and safety of raloxifene for patients with mild to moderate COVID-19.EClinicalMedicine · 2022Article
- Characterization of raloxifene as a potential pharmacological agent against SARS-CoV-2 and its variants.Cell death & disease · 2022Article
- The SARS-CoV-2 spike protein binds and modulates estrogen receptors.bioRxiv : the preprint server for biology · 2022Article
- Article
- Mechanism of Caspase-1 Inhibition by Four Anti-inflammatory Drugs Used in COVID-19 Treatment.International journal of molecular sciences · 2022Article
- Estrogen and Estrogen Receptor Modulators: Potential Therapeutic Strategies for COVID-19 and Breast Cancer.Frontiers in endocrinology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused corona virus disease 2019 (COVID-19) pandemic and led to mass casualty. Even though much effort has been put into development of vaccine and treatment methods to combat COVID-19, no safe and efficient cure has been discovered. Drug repurposing or drug repositioning which is a process of investigating pre-existing drug candidates for novel applications outside their original medical indication can speed up the drug development process. Raloxifene is a selective estrogen receptor modulator (SERM) that has been approved by FDA in 1997 for treatment and prevention of postmenopausal osteoporosis and cancer. Recently, raloxifene demonstrates efficacy in treating viral infections by Ebola, influenza A, and hepatitis C viruses and shows potential for drug repurposing for the treatment of SARS-CoV-2 infection. This review will provide an overview of raloxifene's mechanism of action as a SERM and present proposed mechanisms of action in treatment of viral infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.